Valuation : Acrivon Therapeutics, Inc.

Market Cap 91.28M 78.54M 73.9M 67.51M 126M 8.62B 127M 873M 339M 4.42B 343M 335M 14.24B P/E 2026 *
-1.12x
P/E 2027 * -1.31x
Enterprise Value 91.28M 78.54M 73.9M 67.51M 126M 8.62B 127M 873M 339M 4.42B 343M 335M 14.24B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
84.67%
Yield 2026 *
-
Yield 2027 * -
08-31 Acrivon Therapeutics, Inc. Announces Appointment of Michaela Levin as Chief Business Officer, Effective August 31, 2026 CI
08-12 Acrivon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-05 Acrivon Therapeutics Advances Acr-2316 into Randomized Dose Expansion in Ongoing Phase 1/2 Study CI
05-15 Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) RE
05-13 Acrivon Therapeutics Q1 Loss Narrows MT
05-13 Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-17 Acrivon Therapeutics Inc Highlights Preclinical Data with Three Posters At Aacr Demonstrating Strong Acr-368 and Acr-2316 Synergies with Immune Checkpoint Inhibitors and Adc Payloads CI
04-15 Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) RE
03-19 Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-02 Acrivon Therapeutics, Inc. and Akoya Biosciences Enter into Termination and Transition Agreement CI
02-18 Acrivon Therapeutics, Inc. Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory CI
01-08 Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, Its Next AP3-Enabled Development Candidate, Targeting CDK11 CI
01-08 Acrivon Therapeutics announces positive Acr-368 phase 2b endometrial cancer clinical data RE

Last Transcript : Acrivon Therapeutics, Inc.

1 day+3.40%
1 week+3.40%
Current month+1.91%
1 month+29.88%
3 months+48.95%
6 months+33.12%
Current year-11.62%
1 week 2.02
Extreme 2.0209
2.2
1 month 1.69
Extreme 1.69
2.39
Current year 1.27
Extreme 1.27
3.56
1 year 1.27
Extreme 1.27
3.56
3 years 1.05
Extreme 1.05
12.09
5 years 1.05
Extreme 1.05
25.47
10 years 1.05
Extreme 1.05
25.47
Manager TitleAgeSince
Chief Operating Officer 46 2018-02-28
Chief Executive Officer 64 2018-03-31
Director of Finance/CFO 60 2025-03-31
Director TitleAgeSince
Chairman 64 2018-03-31
Director/Board Member 46 2018-02-28
Director/Board Member 55 2020-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Free

Executive/Senior Manager

160,000 0.3738%
8/25/26 Sell

Chief Executive Officer

-14,036 0.0328%
8/18/26 Sell

General Counsel

-185 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+3.40%+3.40%+60.15%-82.40% 91.28M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.49%+0.82%+72.51%+88.30% 27.51B
Weighted average by Cap. -1.03%+0.11%+89.41%+127.85%

Financials

2026 *2027 *
Net sales - -
Net income -76.59M -65.9M -62M -56.64M -106M -7.23B -106M -733M -284M -3.71B -288M -281M -11.95B -90.84M -78.17M -73.55M -67.19M -126M -8.58B -126M -869M -337M -4.4B -341M -334M -14.18B
Net Debt - -
Logo Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Employees
75
Date Price Change Volume
26-09-04 US$2.130 +3.40% 184,600
26-09-03 US$2.060 -4.19% 118,785
26-09-02 US$2.150 +3.86% 131,319
26-09-01 US$2.070 -0.96% 356,517
26-08-31 US$2.090 +1.46% 160,288
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.130USD
Average target price
11.50USD
Spread / Average Target
+439.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACRV Stock